

## DAFTAR PUSTAKA

1. Fauziati A. Global challenge of early detection and management of chronic kidney disease. *Indonesian Journal of Medicine and Health*. 2017;8:1-3.
2. Hill N, Fatoba ST, Oke JL, Hirst J, Callaghan C, Lasserson D, et al. Global prevalence of chronic kidney disease a systematic review and meta-analysis. *PlosOne*. 2017; 7:1-18.
3. Murphy D, McCulloch C, Lin F, Banerjee T, Bragg-Gresham J, Eberhardt, M, et al. Trends in prevalence of chronic kidney disease in the United States. *Ann Intern Med*. 2016; 165:473-481.
4. Prodjosudjadi W, Suhardjono, Suwitra K, Pranawa, Widiana I, Loekman J, et al. Incidence, prevalence, treatment and cost of end-stage renal disease in Indonesia. *Ethn. Dis*. 2006; 16: 2–14.
5. Tsukamoto Y, Wang H, Becker G, Chen H, Han D, Harris D, et al. Report of the Asian Forum of Chronic Kidney Disease Initiative (AFCKDI) 2007. “Current status and perspective of CKD in Asia”: diversity and specificity among Asian countries. *Clin Exp Nephrol*. 2009;13:249–256.
6. Ardanari S, Alpert M, Aggarwal K. Cardiovascular disease in chronic kidney disease :risk factors, pathogenesis and prevention. *Advances in Peritoneal Dialysis*. 2014; 40:40-54.
7. Lainščak M. Cardiovascular risk in chronic kidney disease. *The Journal of the International Federation of Clinical Chemistry and Laboratory Medicine*. 2009; 20:72-75.
8. Liew Y, Bartholomew J, Demirjian S, Michaels J, Schreiber M. Combined effect of chronic kidney disease and peripheral arterial disease on all-cause mortality in a high risk population. *Clinical Journal American Society Nephrology*. 2008; 3(4):1084-1089.
9. Putri A, Thaha M. Role of oxidative stress on chronic kidney disease progression. *Acta Medica Indonesiana - The Indonesian Journal of Internal Medicine*. 2014; 46:244-253.

10. Xu G, Luo K, Liu H, Huang T, Fang X, Tu W. The progress of inflammation and oxidative stress in patients with chronic kidney disease. *Renal Failure*. 2014; 37(1):45-49.
11. Barreto D, Barreto F, Liabeuf S, Temmar M, Lemke H, Tribouilloy C, et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. *Kidney International*. 2010;77: 550–556.
12. Panichi V, Scatena A, Migliori M, Marchetti V, Paoletti S, Beati S. Biomarkers of chronic inflammatory state in uremia and cardiovascular disease. *International Journal of inflammation*. 2012;5:808-818.
13. Filiopoulos V, Vlassopoulos D. Inflammatory syndrome in chronic kidney disease: pathogenesis and influence on outcomes. *Inflammation & Allergy - Drug Targets*. 2009;8: 369-382.
14. Zhang K, Yin F, Lin L. Circulating endothelial cells and chronic kidney disease. *Biomed Res Int*. 2014; 36:1-7.
15. Satoh M. Endothelial dysfunction as an underlying pathophysiological condition of chronic kidney disease. *Clinical and Experimental Nephrology*. 2012;16:518–521.
16. Bahlmann F, Speer T, Fliser D. Endothelial progenitor cells in chronic kidney disease. *Nephrol Dial Transplant*. 2010;25:341–346.
17. Krenning G, Dankers P, Drouven J, Waanders F, Franseen C, Luyn M, et al. Endothelial progenitor cell dysfunction in patients with progressive chronic kidney disease. *Am J Physiol Renal Physiol*. 2009; 296(6):1314-1322.
18. Goligorsky M, Yasuda K, Ratliff B. Dysfunctional endothelial progenitor cells in chronic kidney disease. *J Am Soc Nephrol*. 2010;21: 911–919.
19. De Groot K, Bahlmann F, Sowa J, Koenig J, Menne J, Haller H, et al. Uremia causes endothelial progenitor cell deficiency. *Kidney International*. 2004;66: 641–646.
20. Jourde-Chiche N, Dou L, Sabatier F, Calaf R. Levels of circulating endothelial progenitor cells are related to uremic toxins and vascular injury in

- hemodialysis patients. *Journal of Thrombosis and Haemostasis*. 2009;7:1576–1584.
21. Bitterli L, Afan S, Buhler S. Endothelial progenitor cells as a biological marker of peripheral artery disease. *Vascular Medicine*. 2016; 21(1):3–11.
  22. Borreros C, Santos M. Peripheral arterial disease in general practice: ankle-brachial index by palpation in the diagnosis of peripheral arterial disease. *Phil Heart Center J*. 2012; 16(2):12-18.
  23. Chen J, Mohler E, Xie D, Shlipak M, Townsend R, Appel L, et al. Risk factors for peripheral arterial disease among patients with chronic kidney disease. *The American Journal of Cardiology*. 2012; 110(1):136-141.
  24. Wang Y, Guo X, Li J, Hu D, Zhaou D, Ma H, et al. Predictive value of ankle-brachial index to all-cause mortality and cardiovascular mortality in Chinese patients with chronic kidney disease. *Vasa*. 2012;41: 205 – 213.
  25. Inker L, Astor B, Fox CH, Isakova T, Lash JP, Peralta CA, Tamura MK, Feldman H. KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD. *Am J Kidney Dis*. 2014;63(5):713-735.
  26. Subbiah A, Chhabra Y, Mahajan S. Cardiovascular disease in patients with chronic kidney disease: a neglected subgroup. *Heart Asia*. 2016; 8:56–61
  27. Bucharles S, Varela A, Barberato S, Filho R. Assessment and management of cardiovascular disease in patients with chronic kidney disease. *J Bras Nefrol*. 2010; 32(1):118-125.
  28. Dewayani R. Penyakit jantung koroner pada “chronic kidney disease”. *Jurnal Kardiologi Indonesia*. 2007; 28:387-395.
  29. Lee B, Ahmed F, Hamm L, Teran F, Chen C, Liu Y. Association of C-reactive protein, tumor necrosis factor-alpha, and interleukin-6 with chronic kidney disease. *BMC Nephrology*. 2015;16:77-80.
  30. Girn H, Orsi N, Vanniasinkam S. An overview of cytokine interactions in atherosclerosis and implications for peripheral arterial disease. *Vascular Medicine*. 2007;12: 299–309.

31. Signorelli S, Viore F, Malaponte G. Inflammation and peripheral arterial disease: The value of circulating biomarkers. *International Journal of Molecular Medicine*. 2014;33:777-783.
32. Chmielewsky M, Lindholm B, Stevinkel P. Vascular effect of inflammation and oxidative stress in CKD. In: Goldsmith D, editors. *Cardio-renal clinical challenges Switzerland*: Springer International Publishing; 2015.51-56.
33. Nanayakkara P, Gaillard C. Vascular disease and chronic renal failure: new insights. *Netherland The Journal of Medicine*. 2010; 68:1-7.
34. Stevinkel P, Ketteler M, Johnson R, Lindholm B, Filho R, Riella M. IL-10, IL-6, and TNF- $\alpha$ : Central factors in the altered cytokine network of uremia—The good, the bad, and the ugly. *Kidney International*. 2005;67; 1216–1233.
35. Su H, Leui C, Zhang C. Interleukin 6 signalling pathway and its role in kidney disease : an update. *frontier in Immunology*. 2017; 8:402-407.
36. Kiewisz J, Kaczmarek M, Pawlowska A, Kmiec Z, Stompor T. Endothelial progenitor cells participation in cardiovascular and kidney diseases: a systematic review. *Acta Biochimica Polonica*. 2016; 63:475-482.
37. Rebić D, Hadžović-Džuvo A, Valjev A. Chronic kidney disease and endothelium. *EMJ Nephrol*. 2015; 3(1):111-117.
38. Burger D, Touyz R. Cellular biomarkers of endothelial health: microparticles, endothelial progenitor cells, and circulating endothelial cells. *Journal of the American Society of Hypertension*. 2012; 6(2):85-89.
39. Martens C, Edwards D. Peripheral vascular dysfunction in chronic kidney disease. *Cardiology Research and Practice*. 2011;26:1-9.
40. Surjadi C. Pemanfaatan sel punca progenitor endothelial (*endothelial progenitor cells*) sebagai biomarker risiko penyakit kardiovaskular. *Cermin Dunia Kedokteran*. 2012; 39:7-13.
41. Liu H, Gong Y, Yu C, Sun Y, Li X, Zhao D, et al. Endothelial progenitor cells in cardiovascular diseases: from biomarker to therapeutic agent. *Regenerative Medicine Research*. 2013; 1(1):9-12.



42. Nababan S, Purba A, Frisca , Aini N, Setiawan B, Sandra F. Peranan endothelial progenitor cell. *Cermin Dunia Kedokteran*. 2007; 34;5.
43. Sen S, Mc Donald S, Coates T, Bonder C. Endothelial progenitor cells: novel biomarker and promising cell therapy for cardiovascular disease. *Clinical Science*. 2011; 120: 263–283.
44. Martins S, Quelhas-Santos J. Circulating endothelial progenitor cells: a review of definition characterization and identification. *Research & Reviews: Research Journal of Biology*. 2016;3:42-50.
45. Lamperti E, Zúñiga F, Ormazábal V, Escudero C, Aguayo C. Vascular regeneration by endothelial progenitor cells in health and diseases. *Intech*. 2016; 10:231-257.
46. Herman h. Endothelial progenitor cell in kidney pathology. *Blood*. 2004; 103:921-926.
47. Hickson L, Eirin A, Lerman O. Challenges and opportunities for stem cell therapy. *Kidney International*. 2016;11:1-12.
48. Mohandas R, Segal M. Endothelial progenitor cells and endothelial vesicles – what is the significance for patients with chronic kidney disease? *Blood Purif*. 2010; 29:158–162.
49. Albu M, Iliuita A, Suzana, Maria GL, Guberna S, Sinescu C. The role of ankle-brachial index for predicting peripheral arterial disease. *Maedica – a Journal of Clinical Medicine*. 2014; 9(3): 295-302.
50. Aboyans V, Criqui M, Abraham P, Allison M, Creager M, Diehm C, et al. Measurement and interpretation of the ankle-brachial index a scientific statement from the American Heart Association. *Circulation*. 2012; 126:2890-2909.
51. Ix J, Katz R, Boer I, Kestenbaum B, Allison M, Siscovick D, et al. Association of chronic kidney disease within spectrum of ABI. *J Am Coll Cardiol*. 2009; 54:1176–84.
52. Grenon M, Gagnon J, Hsiang Y. Ankle–brachial index for assessment of peripheral arterial disease. *N Engl J Med*. 2009; 361(19):40-43.

53. Chen F, Yang C, Yang W, Chen J, Ng Y, Li S, et al. Ankle-brachial index is a powerful predictor of renal outcome and cardiovascular events in patients with chronic kidney disease. *The Scientific World Journal*. 2012; 23:84 – 94.
54. Ghimire M, Pahari B, Das G, Sharma S, Das G. Prevalence of peripheral arterial disease (PAD) in end stage renal disease (ESRD) patients on hemodialysis: a study from Central Nepal. *Kathmandu University Medical Journal*. 2014; 47(3):181-184.
55. Elhakeem H, Sabry R, Ahmed L, Abdallah A, Mansour H, Nassib S. Role of TLR-2, IL-6 and IL-18 in the pathogenesis of Egyptian predialysis CKD patients. *Clinical Medicine and Diagnostics*. 2014; 4(6):118-127.
56. Arroyo D, Betriu A, Valls J, Gorriz J, Pallares V, Abajo M, et al. Factors influencing pathological ankle-brachial index values. *Nephrol Dial Transplant*. 2016; 10: 1–8.
57. Ghanavatian S, Diep L, Barany P, Heimburger O, Seeberger A, Stevinkel P, et al. Subclinical atherosclerosis, endothelial function, and serum inflammatory markers in chronic kidney disease stages 3 to 4. *Vascular Renal Disease*. 2014; 65(5):443-449.
58. Yamasaki S, Izawa A, Koshikawa M, Saigusa T, Ebisawa S, Miura T, et al. Association between estimated glomerular filtration rate and peripheral arterial disease. *J Cardiol*. 2015; 66(5):430-434.
59. Goldberg I, Krause I. The role of gender in chronic kidney disease. *European Medical Journal*. 2016; 1(2):58-64.
60. Ungprasert P, Pornratanarangsi S. Correlation between peripheral arterial disease and stage of chronic kidney disease. *Journal Medical Association Thailand*. 2011; 94:46-50.
61. Ontenddu S, Kumar S, Banode P. Spectrum of ankle-brachial index in chronic kidney disease in rural teaching hospital. *J Integr Nephrol Androl*. 2016; ;3:19-23.
62. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. *Circulation*. 2003;107:87-92

63. Stoica A, Stoica E, Constantinescu I, Uscatescu V, Ginghina C. Interleukin-6 and Interleukin 10 gene polymorphism, endothelial dysfunction, and postoperative prognosis in patients with peripheral arterial disease. *Journal of vascular surgery*. 2010; 52(1):103-109.
64. Coppolini G, Buemi A, Bolignano D, Lacquaniti G, La Spada M, Stilo F, et al. Perioperative iloprost and endothelial progenitor cells in uremic patients with severe limb ischemia undergoing peripheral revascularization. *The Journal of surgical research*. 2009; 57(1):129-135.
65. Jie K, Zaikova M, Bergevoet M, Westerweel P, Rastmanesh M, Blankestijn P, et al. Progenitor cells and vascular function are impaired in patients with chronic kidney disease. *Nephrol Dial Transplant*. 2010; 25: 1875–1882.
66. Dankers P. Renal regenerative medicine: bioengineering of cell-based membranes and antiinflammatory drug delivery. 2013;11:81-91.
67. Teraa M, Sprengers R, Westerweel P, Gremmels H, Goumans M, Teerlink T, et al. Bone marrow alterations and lower endothelial progenitor cell numbers in critical limb ischemia patients. *Plos One*. 2013; 8(1): 1-10.
68. Dai L, Golembiewska E, Lindholm B, Stevinkel P. End-stage renal disease, inflammation and cardiovascular outcomes. *Nephrology*. 2017; 191:32–43.
69. Claro M, Moreno A, Gadotti A, Dolenga C, Nakao L, Azevedo M, et al. The impact of uremic toxicity induced inflammatory response on the cardiovascular burden in chronic kidney disease. *Toxins*. 2018; 10(10): 384-390.
70. Wu C, Hung S, Kuo K, Tarn D. Impact of indoxyl sulfate on progenitor cell-related neovascularization of peripheral arterial disease and post-angioplasty thrombosis of dialysis vascular access. *Toxins*. 2017; 9( 25):1-10.
71. Ozkok A, Yildiz A. Endothelial progenitor cells and kidney diseases. *Kidney and Blood Pressure Research*. 2018; 43(3):701-718.
72. Lin C, Wu C, Wu P, Pan C, Wang T, Sun F, et al. Indoxyl sulfate impairs endothelial progenitor cells and might contribute to vascular dysfunction in patients with chronic kidney disease. *Kidney and Blood Pressure Research*. 2016;41:1025-1036.

73. Hung S, Kuo K, Huang H, Lin C, Tsai T, Wang C, et al. Indoxyl sulfate suppresses endothelial progenitor cell-mediated neovascularization. *Kidney International*. 2016; 89:574–585.
74. Karki P, Jaiswal N, Shrestha N. Ankle brachial index as a predictor for cardiovascular risk factors in patients with chronic kidney disease. 2014;4(2):76-82.

